Search Patents
  • BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
    Publication number: 20240117010
    Abstract: The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: April 11, 2024
    Applicant: Navigo Proteins GmbH
    Inventors: Mathias Kahl, Erik Fiedler, Eva Bosse-Doenecke, Anja Katzschmann, Hanna Bobolowski, Jonathan Lotze, Maren Meysing
  • BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
    Publication number: 20230272050
    Abstract: The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona vims 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 31, 2023
    Applicant: Navigo Proteins GmbH
    Inventors: Mathias Kahl, Erik Fiedler, Eva Bosse-Doenecke, Anja Katzschmann, Hanna Bobolowski, Jonathan Lotze, Maren Meysing
  • Coronavirus Disease 2019(COVID -19) Recombinant Spike Protein Forming Trimer, Method for Mass Producing Recombinant Spike Protein in Plants, and Method for Preparing Vaccine Composition on Basis Thereof
    Publication number: 20230203101
    Abstract: The present invention relates to a recombinant spike protein of the COVID-19 virus forming a trimer and a method for mass-producing the recombinant spike protein, and more specifically to a method for designing a recombinant gene expressing a recombinant spike protein of the COVID-19 virus forming a trimer for the purposes of enhancing immunogenicity and effective antigen delivery, and a method for mass-producing the recombinant spike protein in plants.
    Type: Application
    Filed: April 22, 2021
    Publication date: June 29, 2023
    Applicants: POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION, KOREA NATIONAL INSTITUTE OF HEALTH, BIOAPPLICATIONS INC
    Inventors: In Hwan HWANG, Shijian SONG, Rezaul Islam Khan MD, Haiping DIAO, Eun Ju SOHN, Bo Hwa CHOI, Jang Hoon CHOI, Eun Young JANG, Young Jae LEE
  • MODIFIED SPIKE PROTEIN AND METHOD OF TREATMENT
    Publication number: 20220356212
    Abstract: In one embodiment, the present specification discloses a modified spike (S) protein comprising of SEQ ID NO: 2, the modified spike protein encoded by a gene sequence of SEQ ID NO: 1, and methods of using the modified spike protein as disclosed herein.
    Type: Application
    Filed: March 25, 2022
    Publication date: November 10, 2022
    Applicant: Nanogen Pharmaceutical Biotechnology JSC
    Inventors: Nhan Ho, Si Minh Do, Bruce May
  • INFECTIOUS BRONCHITIS VIRUS (IBV) SPIKE PROTEIN AS SUBUNIT VACCINE
    Publication number: 20140127264
    Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.
    Type: Application
    Filed: March 1, 2012
    Publication date: May 8, 2014
    Inventors: Hèélne Verheije, Carla Christina Schrier
  • Infectious bronchitis virus (IBV) spike protein as subunit vaccine
    Patent number: 9597390
    Abstract: The present invention relates to Infectious bronchitis virus (IBV) spike protein or a fragment thereof comprising a receptor-binding domain, wherein said spike protein or said fragment thereof is C-terminally fused to a trimerisation or tetramerisation domain. Such proteins form trimer or tetramer structures and as such they mimic the natural context of the spike protein. The present invention further relates to subunit vaccines comprising such a protein, to DNA molecules encoding such proteins, to plasmids comprising such DNA molecules, to avian live recombinant carrier viruses (LRCV's) comprising such DNA molecules or plasmids, to vaccines comprising such DNA molecules, plasmids and LRCV's and to combination vaccines comprising an IBV spike protein, DNA molecules, plasmids or LRCV's encoding such a protein, and another IBV vaccine capable of inducing protection against another IBV serotype and/or a vaccine capable of inducing protection against another avian pathogen.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: March 21, 2017
    Assignees: Utrech University, Intervet Inc.
    Inventors: Hélène Verheije, Carla Christina Schrier
  • Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use
    Patent number: 11911461
    Abstract: Disclosed herein are adjuvanted protein vaccines comprising: a SARS-CoV-2 variant C.1.2 modified S1 Spike protein sequence and a non-phospholipid liposome, wherein the protein is encapsulated within the non-phospholipid liposome. The adjuvanted protein vaccines are suitable for subcutaneous administration. Also disclosed herein are modified spike protein sequences containing SARS-CoV-2 variant C.1.2 modified S1 Spike proteins and methods of use of the vaccines and sequences.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: February 27, 2024
    Assignee: D4 Labs, LLC
    Inventors: David Craig Wright, Michael Bowe, Emily Wright, Peter Pushko
  • DNA encoding the Canine coronavirus spike protein
    Patent number: 5661006
    Abstract: The invention is related to a nucleic acid sequence &coding a Canine coronavirus (CCV) spike protein. Such a protein can be used for the immunization of dogs against CCV infection. The nucleic acid sequence encoding the CCV spike protein can be applied for the preparation of the spike protein by means of genetic engineering techniques or can be applied for the preparation of vector vaccines.
    Type: Grant
    Filed: September 19, 1994
    Date of Patent: August 26, 1997
    Assignee: Akzo Nobel N.V.
    Inventors: Thomas David Kay Brown, Brian Colin Horsburgh
  • ENGINEERED SPIKE PROTEINS OF HANTAVIRUSES AND USES THEREOF
    Publication number: 20210000940
    Abstract: Hantavirus spike proteins with modifications to stabilize (Gn/Gc)n heterodimer contacts and/or Gc homodimer contacts and/or Gn/Gn oligomer contacts on the spike to enable their use as immunogens in next-generation vaccine design. The spike proteins have been covalently stabilized by at least one disulphide inter-chain bond between Gn/Gc heterodimers and/or between Gc homodimers and/or between Gn homo-oligomers as they are presented at the surface of infectious virions. Also, spike stabilization by introduction of cavity-filling amino acids with a bulky side chain at the above-mentioned contacts. The spike proteins can be soluble Gn/Gc ectodomains in solution and/or incorporated as (Gn/Gc)n hetero-oligomers onto virus-like particles (VLPs) and/or used for pseudotyping virus vectors and/or form part of a stabilized recombinant virus. The spike proteins can be used to select ligands and/or can be used for preventing or treating infections by one or more hantaviruses.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 7, 2021
    Applicants: FUNDACIÓN CIENCIA PARA LA VIDA, INSTITUT PASTEUR
    Inventors: Nicole TISCHLER, Eduardo Andrés BIGNON SILVA, Félix Augusto REY, Pablo GUARDADO CALVO
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20170340728
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: June 26, 2017
    Publication date: November 30, 2017
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20150337029
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human Antibodies to Middle East Respiratory Syndrome - Coronavirus Spike Protein
    Publication number: 20190351049
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome—Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Application
    Filed: August 2, 2019
    Publication date: November 21, 2019
    Inventors: Christos KYRATSOUS, Neil STAHL, Sumathi SIVAPALASINGAM
  • SARS-COV-2 spike protein binding molecule and application thereof
    Publication number: 20230331822
    Abstract: Provided are a SARS-COV-2 spike protein binding molecule and an application thereof. The binding molecule may specifically bind to a SARS-COV-2 spike protein and contains at least one immunoglobulin single variable domain, may effectively block the binding of the SARS-COV-2-Spike protein to an ACE2 receptor of a human cell, thereby blocking the infection of the cell with SARS-COV-2 and inhibiting SARS-COV-2 infection and amplification.
    Type: Application
    Filed: March 8, 2021
    Publication date: October 19, 2023
    Inventor: Junfang ZHANG
  • Stabilized recombinant hantaviral spike proteins comprising mutations in Gc
    Patent number: 11723968
    Abstract: The present invention describes specific engineering of the hantavirus spike proteins with modifications to stabilize (Gn/Gc)n heterodimer contacts and/or Gc homodimer contacts and/or Gn/Gn oligomer contacts on the spike with the purpose of using them as immunogens in next-generation vaccine design. Said spike proteins have been covalently stabilized by at least one disulphide inter-chain bond between Gn/Gc heterodimers and/or between Gc homodimers and/or between Gn homo-oligomers as they are presented at the surface of infectious virions. It also involves spike stabilization by introduction of cavity-filling amino acids with a bulky side chain at the above-mentioned contacts.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: August 15, 2023
    Assignees: FUNDACION CIENCIA PARA LA VIDA, INSTITUT PASTEUR
    Inventors: Nicole Tischler, Eduardo Andrés Bignon Silva, Félix Augusto Rey, Pablo Guardado Calvo
  • Human antibodies to middle east respiratory syndrome—coronavirus spike protein
    Patent number: 9718872
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: August 1, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Human antibodies to Middle East Respiratory Syndrome—coronavirus spike protein
    Patent number: 10406222
    Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: September 10, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
  • Fatty Acid Complexes Of Coronavirus Spike Protein And Their Use
    Publication number: 20230227506
    Abstract: Complexes of coronavirus spike proteins, as well as fragments or mutants thereof wherein the fragment or mutant thereof at least contains a receptor binding domain of said coronavirus spike protein, with linoleic acid, or a derivative or a salt or a mimetic thereof. Methods for producing the complexes of the invention by incubating coronavirus spike proteins with linoleic acid or a derivative or a salt or a mimetic thereof. . In vitro methods for identifying molecules which have therapeutic potential for diseases caused by coronaviruses by contacting the molecule with a coronavirus spike protein and linoleic acid or a derivative or salt or mimetic thereof. A method of treatment of coronavirus infection by administration of linoleic acid, or a derivative, a salt or a mimetic thereof to a subject in need thereof, by administration of an aerosol formulation or dry powder formulation to the respiratory tract, preferably by nasal administration.
    Type: Application
    Filed: June 18, 2021
    Publication date: July 20, 2023
    Inventors: Daniel Joseph Fitzgerald, Imre Berger, Christiane Berger-Schaffitzel, Christine Toelzer, Kapil Gupta
  • PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF
    Publication number: 20230322837
    Abstract: Provided are stellate compounds that target spike proteins and have a significant anti-SARS-CoV-2 ability and a certain broad spectrum. Such molecules and salts thereof have at least one basic unit R(X)n, which binds at an orthotopic binding site such as an MD domain or an allosteric site, to a virus containing spike proteins or a virus having spike proteins on its surface, thereby preventing coronavirus or other viruses which express spike proteins on their surfaces from invading host cells, and preventing the occurrence of viral infection. In addition, interaction of the molecules and salts thereof with vitamin K-dependent proteins in the human body inhibits the expression of vitamin K so as to inhibit blood coagulation in the human body, thereby treating thrombosis caused by coronavirus and producing a curative effect for pneumonia caused by a severe viral infection.
    Type: Application
    Filed: May 24, 2023
    Publication date: October 12, 2023
    Applicant: SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.
    Inventors: Jun XU, Mengjiao HAO, Yuting ZHANG, Hao CHEN
  • NUTRACEUTICAL FORMULATIONS TO PREVENT, TREAT, AND INHIBIT EXCESS CYTOKINES, SARS-CoV-2 SPIKE PROTEINS, AND mRNA VACCINE SPIKE PROTEINS
    Publication number: 20230038577
    Abstract: Combinations of cannabinoids, vitamins, trace elements, bioactive components, bioflavonoid polyphenols, proteolytic enzymes, amino acids, and antioxidants which work independently and synergistically for the prevention, treatment, and inhibition of excess cytokines caused by the immune response to extreme viral and bacterial infections, including the inhibition of COVID-19, Rhinovirus and/or other virus spike proteins and mRNA vaccine spike proteins from attaching to body organ cells, penetrating cell membranes, and the replication of virus particles and spike proteins inside the cells. Inhibition of inflammation and prevention of long-term side effects, health issues (long-haulers), and disease caused by the SARS-CoV-2 and its variants, Rhinovirus, other viruses, bacteria, and mRNA vaccines are provided by the nutraceutical compositions. Specific combinations of these compounds work synergistically to increase the efficacy of the independent nutraceuticals in treatment.
    Type: Application
    Filed: July 28, 2022
    Publication date: February 9, 2023
    Inventor: Mark A Fluga
  • Stabilizing Mutants of Prefusion Sars-Cov-2 (Covid-19) Spike Protein And Improved Yeast Surface Display Engineering Platform For The Same
    Publication number: 20210355170
    Abstract: The invention relates to one or more mutations configured to stabilize the prefusion “up” protomer trimeric Spike protein from SARS-CoV-2. The inventive technology further relates to systems, methods, and compositions to display one or more proteins on the surface of a yeast cell. Specifically, in one embodiment the invention relates to systems, methods, and compositions to display one or more Spike protein from SARS-CoV-2 on the surface of a yeast cell, and more preferably a Spike protein from SARS-CoV-2 stabilized in its prefusion conformation on the surface of a yeast cell.
    Type: Application
    Filed: May 12, 2021
    Publication date: November 18, 2021
    Inventors: Timothy Whitehead, Monica Kirby, Zachary Baumer, Matthew Bedewitz, Brian Petersen, Paul J. Steiner
Narrow Results

Filter by US Classification